The company’s consolidated revenue will see a drop of 21% YoY, at Rs 1,980 crore. The YoY decline in sales is attributed to the slowing down of Molnupiravir sales as COVID cases fall.
The company’s consolidated revenue will see a drop of 21% YoY, at Rs 1,980 crore. The YoY decline in sales is attributed to the slowing down of Molnupiravir sales as COVID cases fall. The company’s consolidated revenue will see a drop of 21% YoY, at Rs 1,980 crore. The YoY decline in sales is attributed to the slowing down of Molnupiravir sales as COVID cases fall. Moneycontrol Latest News Read More
English 
हिन्दी